肿瘤浸润淋巴细胞过继转移治疗转移性葡萄膜黑色素瘤:单中心、两阶段、单臂2期研究
这项单中心两阶段单臂2期研究纳入21例转移性葡萄膜黑色素瘤患者,采用环磷酰胺联合氟达拉滨预处理后输注自体肿瘤浸润淋巴细胞并给予高剂量白介素-2。20例可评估患者中7例(35%,95%CI 16-59)出现客观肿瘤退缩,3例对既往免疫检查点阻断无效。常见3级及以上毒性为淋巴细胞减少、中性粒细胞减少和血小板减少(各21例[100%]),发生1例治疗相关死亡。
要点
- 20例可评估患者中7例(35%,95%CI 16-59)达到客观肿瘤退缩。
- 缓解者中6例部分缓解、1例完全缓解,3例对既往免疫检查点阻断无效。
- 淋巴细胞减少、中性粒细胞减少、血小板减少各21例(100%)为3级及以上毒性。
核心结论
- 据作者所知,这是首项描述自体肿瘤浸润淋巴细胞过继转移介导转移性葡萄膜黑色素瘤客观肿瘤退缩的报告。
- 这些初步结果挑战了转移性葡萄膜黑色素瘤对免疫治疗耐药的观念,并支持进一步研究该癌种的免疫治疗。
- 优化该T细胞治疗对提高临床缓解频率和该治疗模式的普遍适用性至关重要。
研究设计与样本
- 正在进行的单中心、两阶段、2期、单臂试验,纳入年龄≥16岁、组织学确诊的转移性眼部黑色素瘤患者。
- 关键入组标准为美国东部肿瘤协作组体能状态0或1、进展性转移性疾病及足够的血液学、肾功能和肝功能。
- 通过转移灶切除术获取肿瘤组织以生成自体TIL培养物,随后进行大规模离体扩增。
- 患者接受淋巴细胞清除性预处理化疗(静脉环磷酰胺60 mg/kg每日1次连用2天,随后氟达拉滨25 mg/m2每日1次连用5天),之后单次静脉输注自体TIL,并每8小时给予高剂量白介素-2(720 000 IU/kg)。
- 主要终点为按方案可评估患者中使用实体瘤疗效评价标准1.0版评估的客观肿瘤缓解;此处报告该试验的中期分析。
主要发现
- 2013年6月7日至2016年9月9日期间,共连续入组21例转移性葡萄膜黑色素瘤患者并接受TIL治疗。
- 20例可评估患者中7例(35%,95%CI 16-59)出现客观肿瘤退缩。
- 缓解者中6例达到部分缓解,其中2例仍在持续且尚未达到最大缓解;1例众多肝转移灶达到完全缓解,截至治疗后21个月仍在持续。
- 3例缓解者对既往免疫检查点阻断无效。
- 常见3级或更严重毒性反应与淋巴细胞清除性化疗方案相关,包括淋巴细胞减少、中性粒细胞减少和血小板减少(各21例[100%]患者)、贫血(14例[67%]患者)和感染(6例[29%]患者);另有1例继发于脓毒症所致多器官衰竭的治疗相关死亡。
关键数值与推荐
- 客观肿瘤缓解定义为按实体瘤疗效评价标准1.0版评估的缓解,20例可评估患者中7例(35%,95%CI 16-59)达到。
- 淋巴细胞清除性预处理方案为静脉环磷酰胺60 mg/kg每日1次连用2天,随后氟达拉滨25 mg/m2每日1次连用5天。
- TIL输注后给予高剂量白介素-2 720 000 IU/kg每8小时1次。
临床怎么用
- 作者认为这些初步结果挑战了转移性葡萄膜黑色素瘤对免疫治疗耐药的观念,并支持进一步研究该癌种的免疫治疗。
- 作者认为优化该T细胞治疗对提高临床缓解频率和该治疗模式的普遍适用性至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uveal melanoma is a rare tumour with no established treatments once metastases develop. Although a variety of immune-based therapies have shown efficacy in metastatic cutaneous melanoma, their use in ocular variants has been disappointing. Recently, adoptive T-cell therapy has shown salvage responses in multiple refractory solid tumours. Thus, we sought to determine if adoptive transfer of autologous tumour-infiltrating lymphocytes (TILs) could mediate regression of metastatic uveal melanoma. METHODS: In this ongoing single-centre, two-stage, phase 2, single-arm trial, patients (aged ≥16 years) with histologically confirmed metastatic ocular melanoma were enrolled. Key eligibility criteria were an Eastern Cooperative Oncology Group performance status of 0 or 1, progressive metastatic disease, and adequate haematological, renal, and hepatic function. Metastasectomies were done to procure tumour tissue to generate autologous TIL cultures, which then underwent large scale ex-vivo expansion. Patients were treated with lymphodepleting conditioning chemotherapy (intravenous cyclophosphamide [60 mg/kg] daily for 2 days followed by fludarabine [25 mg/m2] daily for 5 days, followed by a single intravenous infusion of autologous TILs and high-dose interleukin-2 [720 000 IU/kg] every 8 h). The primary endpoint was objective tumour response in evaluable patients per protocol using Response to Evaluation Criteria in Solid Tumors, version 1.0. An interim analysis of this trial is reported here. The trial is registered at ClinicalTrials.gov, number NCT01814046. FINDINGS: From the completed first stage and ongoing expansion stage of this trial, a total of 21 consecutive patients with metastatic uveal melanoma were enrolled between June 7, 2013, and Sept 9, 2016, and received TIL therapy. Seven (35%, 95% CI 16-59) of 20 evaluable patients had objective tumour regression. Among the responders, six patients achieved a partial response, two of which are ongoing and have not reached maximum response. One patient achieved complete response of numerous hepatic metastases, currently ongoing at 21 months post therapy. Three of the responders were refractory to previous immune checkpoint blockade. Common grade 3 or worse toxic effects were related to the lymphodepleting chemotherapy regimen and included lymphopenia, neutropenia, and thrombocytopenia (21 [100%] patients for each toxicity); anaemia (14 [67%] patients); and infection (six [29%] patients). There was one treatment-related death secondary to sepsis-induced multiorgan failure. INTERPRETATION: To our knowledge, this is the first report describing adoptive transfer of autologous TILs to mediate objective tumour regression in patients with metastatic uveal melanoma. These initial results challenge the belief that metastatic uveal melanoma is immunotherapy resistant and support the further investigation of immune-based therapies for this cancer. Refinement of this T-cell therapy is crucial to improve the frequency of clinical responses and the general applicability of this treatment modality. FUNDING: Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.
引用
- Chandran SS, Somerville RPT, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017. PMID: 28395880. doi:10.1016/S1470-2045(17)30251-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。